前列地尔联合氯沙坦钾治疗早期糖尿病肾病的疗效及对血清炎症因子的影响  被引量:6

Analysis of Curative Effects of Alprostadil Combined with Losartan potassium on Early Diabetic Nephropathy and Influences on Serum Inflammatory Factors

在线阅读下载全文

作  者:田利娜[1] 陈清萍[1] 王稻[1] 廖雯[1] 曹珊[1] 

机构地区:[1]萍乡市人民医院肾内科,江西萍乡337000

出  处:《长江大学学报(自科版)(下旬)》2016年第12期14-15,共2页Journal of Yangtze University

摘  要:目的:探析前列地尔联合氯沙坦钾治疗早期糖尿病肾病的疗效及对血清炎症因子的影响。方法:2014年1月至2016年1月期间,将早期糖尿病肾病患者78例以随机法进行分组治疗。对照组39例,给予其常规治疗,观察组39例,在常规治疗的基础上增加前列地尔+氯沙坦钾的方式进行治疗。对两组患者的临床治疗效果及血清炎症因子影响情况进行对比。结果:在治疗有效率上,观察组患者高于对照组(94.87%>74.36%),差异具有统计学意义(P<0.05);在血清炎症因子改善情况上,观察组亦同样优于对照组,差异亦具有统计学意义(P<0.05)。结论:对早期糖尿病肾病患者实施前列地尔+氯沙坦钾的联合治疗可显著提升其临床治疗效果,并改善其血清炎症因子水平。Objective:To explore and analyze the curative effects of alprostadil combined with losartan potassium in the treatment of early diabetic nephropathy and influences on serum inflammatory factors.Methods:78cases of early diabetic nephropathy from January 2014 to January 2016 had been randomly divided into two groups:39patients in the control group treated with conventional treatment,39 cases in the observation group with alprostadil+ losartan potassium on the basis of the conventional therapy.The clinical therapeutic effects and the influences on serum inflammatory factors had been compared between the two groups.Results:The effective rate in the observation group(94.87%)was much higher than that in the control group(74.36%)and the difference was statistically significant(P<0.05);improvement of serum inflammatory factors in the observation group was also better than the control group,the difference being statistically significant(P <0.05).Conclusion:The combined treatment of early diabetic nephropathy patients with alprostadil+losartan potassium can significantly improve the clinical effects,and lessen the level of serum inflammatory factors.

关 键 词:前列地尔 氯沙坦钾 早期糖尿病肾病 血清炎症因子 

分 类 号:R587.2[医药卫生—内分泌]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象